20/20 Biolabs misses 10-Q deadline, cites reporting delay

20/20 Biolabs, Inc. notified the SEC it could not file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Rhea-AI Filing Summary

20/20 Biolabs, Inc. notified the SEC it could not file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The company attributes the delay to unanticipated completion delays for its financial statements and related portions of the Form 10-Q and expects to file the Form 10-Q no later than five calendar days after the prescribed due date under Rule 12b-25. The notification was signed by Chief Executive Officer Jonathan Cohen on May 15, 2026.

Insights

Corporate SEC Compliance Counsel

Late-filing notice cites standard Rule 12b-25 relief and a short, five-day extension.

The company states the delay arises from unanticipated completion timing for financial statements and related Form 10-Q sections and invokes Rule 12b-25 to permit filing within five calendar days of the prescribed due date. This is a procedural disclosure rather than a substantive earnings revision.

Key dependencies are completion of the financial statements and any required accountant exhibits. Subsequent filings will show whether reported results change materially; timing and cash-flow treatment are not described in this excerpt.

Key Figures

Form period end: March 31, 2026 Extension window: five calendar days Contact phone: 240-453-6339 +1 more

4 metrics

Form period end March 31, 2026 Quarter end for the delayed Form 10-Q

Extension window five calendar days Anticipated filing timeframe under Rule 12b-25

Contact phone 240-453-6339 Contact for this notification: Jonathan Cohen

Notification signed May 15, 2026 Date the Form 12b-25 notification was executed

Key Terms

Rule 12b-25, Form 10-Q, prescribed due date

3 terms

Rule 12b-25 regulatory

"The Registrant is unable to file its Quarterly Report on Form 10-Q . . . In accordance with Rule 12b-25"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

prescribed due date regulatory

"will be filed on or before the fifth calendar day following the prescribed due date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did 20/20 Biolabs (AIDX) file a Form 12b-25 for the quarter ended March 31, 2026?

The company cites unanticipated delays in completing its financial statements and related portions of the Form 10-Q. It invoked Rule 12b-25 and anticipates filing within five calendar days after the prescribed due date.

When does 20/20 Biolabs expect to file the delayed Form 10-Q?

The registrant anticipates filing the Form 10-Q no later than five calendar days following the prescribed due date, per the Rule 12b-25 statement signed on May 15, 2026 by the CEO.

Does the Form 12b-25 say the March 31, 2026 results will materially change?

The filing does not indicate any anticipated significant change in results; the company answered the corresponding question with No in the provided excerpt and did not attach quantitative revisions.

Who can be contacted about 20/20 Biolabs' late filing notice?

The filing lists Jonathan Cohen as the contact with telephone number 240-453-6339. That contact is identified for inquiries regarding this Form 12b-25 notification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:20 PM EDT Learn about SEC filing dates

	UNITED STATES
	SECURITIES AND EXCHANGE COMMISSION
	Washington, D.C. 20549
		SEC FILE NUMBER
	FORM 12b-25	001-43128
	NOTIFICATION OF LATE FILING	CUSIP NUMBER
		90138K101

(Check one):	☐ Form 10-K	☐Form 20-F	☐ Form 11-K
	☒ Form 10-Q	☐ Form 10-D	☐ Form N-CEN	☐ Form N-CSR

For Period Ended: March 31, 2026

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

☐ For the Transition Period Ended:                                                                                                      

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

20/20 Biolabs, Inc.

Full Name of Registrant

N/A

Former Name if Applicable

15810 Gaither Road, Suite 235

Address of Principal Executive Office (Street and Number)

Gaithersburg, MD 20877

City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 (the “Form 10-Q”) because of unanticipated delays in the completion of its financial statements and related portions of the Form 10-Q, which delays could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 under the Securities Exchange Act of 1934, as amended, the Registrant anticipates filing its Form 10-Q no later than five calendar days following the prescribed due date.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification.

Jonathan Cohen		240		453-6339
(Name)		(Area Code)		(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).   Yes  ☒ No ☐

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?  Yes ☐   No ☒

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

20/20 Biolabs, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2026	By:	/s/ Jonathan Cohen
		Jonathan Cohen
		Chief Executive Officer

3